An early clinical trial has found that the experimental cancer drug manufactured by Pfizer has shown positive results in treating breast cancer in women who are at advanced stage.
Pfizer, the world’s second largest drug maker, has said that the new drug helped in preventing breast cancer from worsening for 20.2 months in a trial that involved 165 women.
The new experimental drug has been named Palbociclib. It is among a new class of cancer drugs that target specific proteins to block tumors.
Erik Gordon, who is a business professor at the University of Michigan, has raised doubts over the drug, saying the outcome was not as positive as some initial results reported earlier in the trial.
Gordon studies the biomedical industry and is not associated with the trial.
However, he said, “There’s been a lot of hope surrounding this class of cancer drugs, and this keeps that hope alive.”
The findings of the clinical trial were released on Sunday at the American Association of Cancer Research in San Diego, California.
Less than 10 percent women accurately estimates breast cancer risk: Survey
Breast cancers are becoming common disease now-a-days. A survey says fewer than 10% of women accurately estimate their risk of breast cancer.
A survey of 10,000 women showed that women usually fail to accurately measure the symptoms as they are equally likely to overestimate or underestimate the risk of the disease.
Compared with estimates derived from validated risk formulas, 9.4% of the women provided estimates that were in line with the calculated risk. About 45% of the remaining participates underestimated their risk and 46% overestimated the risk.
Follow these tips to reduce breast cancer risk
• Avoid weight gain and obesity
• Engage in regular physical activity
• Minimize alcohol intake
• Eat healthy
• Don’t smoke